 I. Assess the rate of disease control i.e., lack of disease progression, a combined rate of objective complete and partial response, and stable disease for at least 4 cycles of therapy in patients with AZD0530 saracatinib in patients with advanced non-small cell lung cancer that had previously been treated with platinum-based combination chemotherapy. 